Genmab, BioNTech Expand Deal To Jointly Develop Novel Immunotherapies For Cancer Patients

Biotechnology companies Genmab A/S (GMAB) and BioNTech SE (BNTX) announced Friday an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

Under the expansion, Denmark -based Genmab and Germany's BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications.

The companies will jointly develop and commercialize, monospecific antibodies leveraging Genmab's proprietary HexaBody technology platform, subject to regulatory approval.

The first monospecific antibody candidate, GEN1053/BNT313, is expected to enter clinical trials by the end of 2022.

GEN1053/BNT313 is a CD27 antibody based on the HexaBody technology, specifically engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell membrane of the T cells.

Under the deal terms, the companies will equally share the development costs and potential future profit deriving from GEN1053/BNT313.

Genmab and BioNTech have been working since 2015 on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options for cancer patients.

The companies currently have two jointly developed investigational medicines in clinical testing since 2019, fusing BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT